Cytochrome P450 Family 1 Inhibitors and Structure-Activity Relationships

With the widespread use of O-alkoxyresorufin dealkylation assays since the 1990s, thousands of inhibitors of cytochrome P450 family 1 enzymes (P450s 1A1, 1A2, and 1B1) have been identified and studied. Generally, planar polycyclic molecules such as polycyclic aromatic hydrocarbons, stilbenoids, and flavonoids are considered to potentially be effective inhibitors of these enzymes, however, the details of the structure-activity relationships and selectivity of these inhibitors are still ambiguous. In this review, we thoroughly discuss the selectivity of many representative P450 family 1 inhibitors reported in the past 20 years through a meta-analysis.

[1]  K. Tsai,et al.  Inhibition of CYP1 by berberine, palmatine, and jatrorrhizine: selectivity, kinetic characterization, and molecular modeling. , 2013, Toxicology and applied pharmacology.

[2]  Ming Zhao,et al.  Pyranoflavones: a group of small-molecule probes for exploring the active site cavities of cytochrome P450 enzymes 1A1, 1A2, and 1B1. , 2013, Journal of medicinal chemistry.

[3]  G. Szklarz,et al.  Human Cytochrome P450 1A1 Structure and Utility in Understanding Drug and Xenobiotic Metabolism* , 2013, The Journal of Biological Chemistry.

[4]  J. Sridhar,et al.  Development of flavone propargyl ethers as potent and selective inhibitors of cytochrome P450 enzymes 1A1 and 1A2. , 2013, Drug metabolism letters.

[5]  Sangkyu Lee,et al.  In vitro inhibitory effect of luotonin A on human CYP1A , 2012, Archives of Pharmacal Research.

[6]  Charlotte M. Miller,et al.  Isolation, biological activity and synthesis of the natural product ellipticine and related pyridocarbazoles , 2012 .

[7]  J. J. Espinosa-Aguirre,et al.  Bergamottin is a competitive inhibitor of CYP1A1 and is antimutagenic in the Ames test. , 2012, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[8]  A. Rimando,et al.  Design, synthesis and evaluation of the inhibitory selectivity of novel trans-resveratrol analogues on human recombinant CYP1A1, CYP1A2 and CYP1B1. , 2012, Bioorganic & medicinal chemistry.

[9]  A. Loaiza-Pérez,et al.  Aryl hydrocarbon receptor activation by aminoflavone: new molecular target for renal cancer treatment. , 2012, International journal of oncology.

[10]  J. Sridhar,et al.  7-Ethynylcoumarins: selective inhibitors of human cytochrome P450s 1A1 and 1A2. , 2012, Chemical research in toxicology.

[11]  F. Guengerich,et al.  Contributions of human enzymes in carcinogen metabolism. , 2012, Chemical research in toxicology.

[12]  J. Sridhar,et al.  Inhibition of cytochrome p450 enzymes by quinones and anthraquinones. , 2012, Chemical research in toxicology.

[13]  Wei-Min Zhang,et al.  Effect of CYP1A1 MSPI polymorphism on the relationship between TP53 mutation and CDKN2A hypermethylation in non-small cell lung cancer. , 2011, Archives of medical research.

[14]  J. Xu,et al.  CYP1A1 Ile462Val polymorphism and susceptibility to lung cancer: a meta-analysis based on 32 studies , 2011, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[15]  Changhui Liu,et al.  Induction of cytochromes P450 1A1 and 1A2 by tanshinones in human HepG2 hepatoma cell line. , 2011, Toxicology and applied pharmacology.

[16]  H. Yamazaki,et al.  Structure-function relationships of inhibition of human cytochromes P450 1A1, 1A2, 1B1, 2C9, and 3A4 by 33 flavonoid derivatives. , 2010, Chemical research in toxicology.

[17]  Eric F. Johnson,et al.  Structural Characterization of the Complex between α-Naphthoflavone and Human Cytochrome P450 1B1* , 2010, The Journal of Biological Chemistry.

[18]  F. Gonzalez,et al.  Cytochrome P450 1B1 Contributes to Angiotensin II-Induced Hypertension and Associated Pathophysiology , 2010, Hypertension.

[19]  T. Itoh,et al.  Selective inhibition of methoxyflavonoids on human CYP1B1 activity. , 2010, Bioorganic & medicinal chemistry.

[20]  S. Yamaori,et al.  Characterization of major phytocannabinoids, cannabidiol and cannabinol, as isoform-selective and potent inhibitors of human CYP1 enzymes. , 2010, Biochemical pharmacology.

[21]  Bo Wang,et al.  Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2 , 2010, Drug metabolism reviews.

[22]  Thomas K. H. Chang,et al.  Inhibition of procarcinogen‐bioactivating human CYP1A1, CYP1A2 and CYP1B1 enzymes by melatonin , 2010, Journal of pineal research.

[23]  T. Minouchi,et al.  Preferential inhibition of CYP1A enzymes in hepatic microsomes by mexiletine , 1999, European Journal of Drug Metabolism and Pharmacokinetics.

[24]  W. Daniel,et al.  Perazine at therapeutic drug concentrations inhibits human cytochrome P450 isoenzyme 1A2 (CYP1A2) and caffeine metabolism — an in vitro study , 2009, Pharmacological reports : PR.

[25]  Wei Duan,et al.  Insights into the structure, function, and regulation of human cytochrome P450 1A2. , 2009, Current drug metabolism.

[26]  Y. Chun,et al.  Potent inhibition of human cytochrome P450 1B1 by tetramethoxystilbene. , 2009, Toxicology letters.

[27]  B. Cravatt,et al.  A suite of activity-based probes for human cytochrome P450 enzymes. , 2009, Journal of the American Chemical Society.

[28]  A. D. Rodrigues,et al.  Further Assessment of 17α-Ethinyl Estradiol as an Inhibitor of Different Human Cytochrome P450 Forms in Vitro , 2009, Drug Metabolism and Disposition.

[29]  Hiroshi Yamazaki,et al.  Reverse type I binding spectra of human cytochrome P450 1B1 induced by flavonoid, stilbene, pyrene, naphthalene, phenanthrene, and biphenyl derivatives that inhibit catalytic activity: a structure-function relationship study. , 2009, Chemical research in toxicology.

[30]  D. Spandidos,et al.  Cytochrome P450 CYP1A1: wider roles in cancer progression and prevention , 2009, BMC Cancer.

[31]  K. Sailaja,et al.  Association of CYP1A1*2 polymorphisms with breast cancer risk: a case control study. , 2009, Indian journal of medical sciences.

[32]  H. Yamazaki,et al.  Interaction of polycyclic aromatic hydrocarbons with human cytochrome P450 1B1 in inhibiting catalytic activity. , 2008, Chemical research in toxicology.

[33]  Guangji Wang,et al.  Inhibitory Effects of Seven Components of Danshen Extract on Catalytic Activity of Cytochrome P450 Enzyme in Human Liver Microsomes , 2008, Drug Metabolism and Disposition.

[34]  W. Baer-Dubowska,et al.  Thiomethylstilbenes as inhibitors of CYP1A1, CYP1A2 and CYP1B1 activities. , 2008, Molecular nutrition & food research.

[35]  Namandjé N. Bumpus,et al.  Mechanism-based inactivation of human cytochromes p450s: experimental characterization, reactive intermediates, and clinical implications. , 2008, Chemical research in toxicology.

[36]  P. Neuvonen,et al.  Celecoxib is a CYP1A2 inhibitor in vitro but not in vivo , 2008, European Journal of Clinical Pharmacology.

[37]  R. D. Bruno,et al.  Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development. , 2007, Bioorganic & medicinal chemistry.

[38]  C David Stout,et al.  Adaptations for the Oxidation of Polycyclic Aromatic Hydrocarbons Exhibited by the Structure of Human P450 1A2*♦ , 2007, Journal of Biological Chemistry.

[39]  H. Yamazaki,et al.  Different mechanisms for inhibition of human cytochromes P450 1A1, 1A2, and 1B1 by polycyclic aromatic inhibitors. , 2007, Chemical research in toxicology.

[40]  H. Ciolino,et al.  A novel synthetic analogue of a constituent of Isodon excisus inhibits transcription of CYP1A1, -1A2 and -1B1 by preventing activation of the aryl hydrocarbon receptor. , 2006, Carcinogenesis.

[41]  D. Nebert,et al.  The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis , 2006, Nature Reviews Cancer.

[42]  P. Neuvonen,et al.  Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects. , 2006, British journal of clinical pharmacology.

[43]  B. Patil,et al.  Furocoumarins from grapefruit juice and their effect on human CYP 3A4 and CYP 1B1 isoenzymes. , 2006, Bioorganic & medicinal chemistry.

[44]  Z. Dvořák,et al.  Silybin and dehydrosilybin inhibit cytochrome P450 1A1 catalytic activity: A study in human keratinocytes and human hepatoma cells , 2006, Cell Biology and Toxicology.

[45]  Y. Moon,et al.  Dietary flavonoids: effects on xenobiotic and carcinogen metabolism. , 2006, Toxicology in vitro : an international journal published in association with BIBRA.

[46]  J. van Grevenynghe,et al.  Potent inhibition of carcinogen-bioactivating cytochrome P450 1B1 by the p53 inhibitor pifithrin alpha. , 2006, Carcinogenesis.

[47]  Y. Chun,et al.  MODULATION OF HUMAN CYTOCHROME P450 1B1 EXPRESSION BY 2,4,3′,5′-TETRAMETHOXYSTILBENE , 2005, Drug Metabolism and Disposition.

[48]  M. Stiborová,et al.  Antitumor drug ellipticine inhibits the activities of rat hepatic cytochromes P450. , 2005, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia.

[49]  J. Giesy,et al.  Activation of the aryl hydrocarbon receptor by berberine in HepG2 and H4IIE cells: Biphasic effect on CYP1A1. , 2005, Biochemical pharmacology.

[50]  D. Schrenk,et al.  Natural furocoumarins as inducers and inhibitors of cytochrome P450 1A1 in rat hepatocytes. , 2005, Biochemical pharmacology.

[51]  A. Takagi,et al.  Effect of antifungal drugs on cytochrome P450 (CYP) 1A2, CYP2D6, and CYP2E1 activities in human liver microsomes. , 2005, Biological & pharmaceutical bulletin.

[52]  F. Guengerich,et al.  Cytochrome P450 activation of arylamines and heterocyclic amines. , 2005, Annual review of pharmacology and toxicology.

[53]  Y. Chun,et al.  POTENT INHIBITION OF RECOMBINANT HUMAN CYTOCHROME P-450 1A1 BY PENTAMETHOXYSTILBENE , 2004, Journal of toxicology and environmental health. Part A.

[54]  B. Haab,et al.  Oltipraz, 3H-1,2-dithiole-3-thione, and sulforaphane induce overlapping and protective antioxidant responses in murine microglial cells. , 2004, Toxicology letters.

[55]  R. Remmel,et al.  Inhibition of murine cytochrome P4501A by tacrine: in vitro studies. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[56]  O. Fardel,et al.  Inhibition of carcinogen-bioactivating cytochrome P450 1 isoforms by amiloride derivatives. , 2004, Biochemical pharmacology.

[57]  Y. Chun,et al.  Potent inhibition of human cytochrome P450 1 enzymes by dimethoxyphenylvinyl thiophene , 2004, Archives of pharmacal research.

[58]  Chieh-fu Chen,et al.  Induction of CYP1A by a diterpene quinone tanshinone IIA isolated from a medicinal herb Salvia miltiorrhiza in C57BL/6J but not in DBA/2J mice. , 2004, Life sciences.

[59]  A. D. Rodrigues,et al.  Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[60]  D. Lewis,et al.  Effect of structural modification on the inhibitory selectivity of rutaecarpine derivatives on human CYP1A1, CYP1A2, and CYP1B1. , 2003, Bioorganic & medicinal chemistry letters.

[61]  F. Berthou,et al.  Differential inhibition of human cytochrome P450 enzymes by epsilon-viniferin, the dimer of resveratrol: comparison with resveratrol and polyphenols from alcoholized beverages. , 2003, Life sciences.

[62]  J. Xu,et al.  Resveratrol, a natural aryl hydrocarbon receptor antagonist, protects lung from DNA damage and apoptosis caused by benzo[a]pyrene , 2003, Journal of applied toxicology : JAT.

[63]  F. Guengerich,et al.  Diterpene quinone tanshinone IIA selectively inhibits mouse and human cytochrome P4501A2 , 2003, Xenobiotica; the fate of foreign compounds in biological systems.

[64]  K. Monostory,et al.  A study on CYP1A inhibitory action of E-2-(4'-methoxybenzylidene)-1-benzosuberone and some related chalcones and cyclic chalcone analogues. , 2003, Toxicology.

[65]  T. Shimada,et al.  Tissue-specific induction of cytochromes P450 1A1 and 1B1 by polycyclic aromatic hydrocarbons and polychlorinated biphenyls in engineered C57BL/6J mice of arylhydrocarbon receptor gene. , 2003, Toxicology and applied pharmacology.

[66]  T. Shimada,et al.  Cytochrome P450 1B1: a target for inhibition in anticarcinogenesis strategies. , 2003, Mutation research.

[67]  L. Leung,et al.  Baicalein inhibits DMBA-DNA adduct formation by modulating CYP1A1 and CYP1B1 activities. , 2002, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[68]  Y. Chun,et al.  Design, Synthesis, and Discovery of Novel trans‐Stilbene Analogues as Potent and Selective Human Cytochrome P450 1B1 Inhibitors. , 2002 .

[69]  Lie-Chwen Lin,et al.  The alkaloid rutaecarpine is a selective inhibitor of cytochrome P450 1A in mouse and human liver microsomes. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[70]  H. Kleiner,et al.  Role of cytochrome P450 1a1 and 1b1 in the metabolic activation of 7,12-dimethylbenz[a]anthracene and the effects of naturally occurring furanocoumarins on skin tumor initiation. , 2002, Chemical research in toxicology.

[71]  F. Guengerich,et al.  A new selective and potent inhibitor of human cytochrome P450 1B1 and its application to antimutagenesis. , 2001, Cancer research.

[72]  Y. Chun,et al.  Mechanism-based inhibition of human cytochrome P450 1A1 by rhapontigenin. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[73]  P. Neuvonen,et al.  Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes , 2001, European Journal of Clinical Pharmacology.

[74]  W. Chan,et al.  Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4. , 2000, Life sciences.

[75]  K. Inouye,et al.  Inhibitory effects of 1,4-naphthoquinone derivatives on rat cytochrome P4501A1-dependent monooxygenase activity in recombinant yeast microsomes. , 2000, Journal of biochemistry.

[76]  M. Burke,et al.  Bioflavonoids: selective substrates and inhibitors for cytochrome P450 CYP1A and CYP1B1. , 2000, Toxicology.

[77]  A. Guillouzo,et al.  Inhibition of human cytochrome P450 enzymes by 1,2-dithiole-3-thione, oltipraz and its derivatives, and sulforaphane. , 2000, Chemical research in toxicology.

[78]  Charles V. Smith,et al.  Potentiation of oxygen-induced lung injury in rats by the mechanism-based cytochrome P-450 inhibitor, 1-aminobenzotriazole. , 2000, The Journal of pharmacology and experimental therapeutics.

[79]  H. Ashida,et al.  Cytochrome P4501A1-Inhibitory Action of Antimutagenic Anthraquinones in Medicinal Plants and the Structure-activity Relationship , 2000, Bioscience, biotechnology, and biochemistry.

[80]  F. Guengerich,et al.  Plasmid-mediated expression of the UmuDC mutagenesis proteins in an Escherichia coli strain engineered for human cytochrome P450 1A2-catalyzed activation of aromatic amines. , 1999, Mutation research.

[81]  Ian L. Rogers,et al.  Resveratrol has antagonist activity on the aryl hydrocarbon receptor: implications for prevention of dioxin toxicity. , 1999, Molecular pharmacology.

[82]  F. Guengerich,et al.  Resveratrol is a selective human cytochrome P450 1A1 inhibitor. , 1999, Biochemical and biophysical research communications.

[83]  H. Ciolino,et al.  Dietary flavonols quercetin and kaempferol are ligands of the aryl hydrocarbon receptor that affect CYP1A1 transcription differentially. , 1999, The Biochemical journal.

[84]  H. Ciolino,et al.  The flavonoid galangin is an inhibitor of CYP1A1 activity and an agonist/antagonist of the aryl hydrocarbon receptor , 1999, British Journal of Cancer.

[85]  H. Ciolino,et al.  Resveratrol inhibits transcription of CYP1A1 in vitro by preventing activation of the aryl hydrocarbon receptor. , 1998, Cancer research.

[86]  S. Zhai,et al.  Comparative inhibition of human cytochromes P450 1A1 and 1A2 by flavonoids. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[87]  H. Yamazaki,et al.  Selectivity of polycyclic inhibitors for human cytochrome P450s 1A1, 1A2, and 1B1. , 1998, Chemical research in toxicology.

[88]  D. Glaise,et al.  Effects of administration of the chemoprotective agent oltipraz on CYP1A and CYP2B in rat liver and rat hepatocytes in culture. , 1997, Carcinogenesis.

[89]  M. Foroozesh,et al.  Aryl acetylenes as mechanism-based inhibitors of cytochrome P450-dependent monooxygenase enzymes. , 1997, Chemical research in toxicology.

[90]  W. Baer-Dubowska,et al.  Inhibitory effects of naturally occurring coumarins on the metabolic activation of benzo[a]pyrene and 7,12-dimethylbenz[a]anthracene in cultured mouse keratinocytes. , 1997, Carcinogenesis.

[91]  W. Baer-Dubowska,et al.  Mechanism-based inactivation of hepatic ethoxyresorufin O-dealkylation activity by naturally occurring coumarins. , 1996, Chemical research in toxicology.

[92]  J. Liehr,et al.  4-Hydroxylation of estrogens as marker of human mammary tumors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[93]  R. Vestal,et al.  Relative potency of mexiletine, lidocaine, and tocainide as inhibitors of rat liver CYP1A1 activity. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[94]  H. Lee,et al.  Structure-activity relationships of anthraquinones as inhibitors of 7-ethoxycoumarin O-deethylase and mutagenicity of 2-amino-3-methylimidazo[4,5-f]quinoline. , 1995, Mutation research.

[95]  S. Loft,et al.  Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. , 1995, British journal of clinical pharmacology.

[96]  J. DiGiovanni,et al.  Inhibition and inactivation of murine hepatic ethoxy- and pentoxyresorufin O-dealkylase by naturally occurring coumarins. , 1993, Chemical research in toxicology.

[97]  S. Safe,et al.  6-substituted 3,4-benzocoumarins: a new structural class of inducers and inhibitors of CYP1A1-dependent activity. , 1993, Archives of biochemistry and biophysics.

[98]  W. Trager,et al.  Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. , 1993, Chemical research in toxicology.

[99]  P. Hollenberg,et al.  Mechanism-based inactivation of cytochrome P450 2B1 by 2-ethynylnaphthalene: identification of an active-site peptide. , 1993, Chemical research in toxicology.

[100]  R. Tukey,et al.  Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. , 1993, The Journal of pharmacology and experimental therapeutics.

[101]  P. Ortiz de Montellano,et al.  Determinants of protein modification versus heme alkylation: inactivation of cytochrome P450 1A1 by 1-ethynylpyrene and phenylacetylene. , 1993, Chemical research in toxicology.

[102]  B. Mico,et al.  1-Aminobenzotriazole-induced destruction of hepatic and renal cytochromes P450 in male Sprague-Dawley rats. , 1992, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[103]  P. Ortiz de Montellano Mechanism-based inactivation of cytochrome P450: isolation and characterization of N-alkyl heme adducts. , 1991, Methods in enzymology.

[104]  A. Boobis,et al.  Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. , 1990, British journal of clinical pharmacology.

[105]  M. P. Arlotto,et al.  6-Methyl-1,3,8-trichlorodibenzofuran as a 2,3,7,8-tetrachlorodibenzo-p-dioxin antagonist: inhibition of the induction of rat cytochrome P-450 isozymes and related monooxygenase activities. , 1988, Molecular pharmacology.

[106]  H. Mukhtar,et al.  Inhibition of epidermal xenobiotic metabolism in SENCAR mice by naturally occurring plant phenols. , 1987, Cancer research.

[107]  J. Segura,et al.  Accumulation of caffeine in healthy volunteers treated with furafylline. , 1987, British journal of clinical pharmacology.

[108]  P. Ortiz de Montellano,et al.  Branchpoint for heme alkylation and metabolite formation in the oxidation of arylacetylenes by cytochrome P-450. , 1985, The Journal of biological chemistry.

[109]  P. Ortiz de Montellano,et al.  Self-catalyzed inactivation of hepatic cytochrome P-450 by ethynyl substrates. , 1980, The Journal of biological chemistry.